Search

Your search keyword '"Jharap, Bindia"' showing total 26 results
Start Over Author "Jharap, Bindia" Publication Year Range Last 3 years
26 results on '"Jharap, Bindia"'

1. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease

Author

Mahmoud, Remi, Savelkoul, Edo H.J., Mares, Wout, Goetgebuer, Rogier, Witteman, Ben J.M., de Koning, Daan B., van Tuyl, Sebastiaan A.C., Minderhoud, Itta, Lutgens, Maurice W.M. D., Akol-Simsek, Dilek, van Schaik, Fiona D.M., Fidder, Herma H., Jansen, Jeroen M., van Boeckel, Petra G.A., Mahmmod, Nofel, Horjus-Talabur Horje, Carmen S., Römkens, Tessa E.H., Colombel, Jean-Frédéric, Hoentjen, Frank, Jharap, Bindia, and Oldenburg, Bas

Published
2023
Full Text
View/download PDF

2. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

Author

Schlotter, Malena, van Workum, Martine, de Jong, Dirk, van Dop, Willemijn, van der Marel, S., El Ghabzouri, Hayat, Talhaoui, Kamila, Oldenburg, Bas, Boontje, Nynke, Fidder, Herma, Hirdes, Meike, Creemers, Rob H., Hoekstra, J., Smid, Jael, Mujagic, Zlatan, François-Verweij, Marthe, Schakel- van den Berge, Toos, Maljaars, Jeroen, Theeuwen, Rosaline, van den Berg, Denise, Gerretsen, Suzanne, Yocarini, Xenia, D’Haens, Geert, Lowenberg, Mark, Grootjans, Joep, Gecse, Krisztina, Bouma, Gerd, Waaijenberg, Petra, Muskens, Bart, Straatmijer, Tessa, Biemans, Vince B.C., Visschedijk, Marijn, Hoentjen, Frank, de Vries, Annemarie, van Bodegraven, Adriaan A., Bodelier, Alexander, de Boer, Nanne K.H., Dijkstra, Gerard, Festen, Noortje, Horjus, Carmen, Jansen, Jeroen M., Jharap, Bindia, Mares, Wout, van Schaik, Fiona D.M., Ponsioen, Cyriel, Romkens, Tessa, Srivastava, Nidhi, van der Voorn, Michael M.P. J.A., West, Rachel, van der Woude, Janneke, Wolvers, Marije D.J., Pierik, Marieke, van der Meulen-de Jong, Andrea E., and Duijvestein, Marjolijn

Published
2023
Full Text
View/download PDF

4. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Author

Rocca, Rodolfo, Lopes, Susana, Caprioli, Flavio, Ardizzone, Sandro, Echarri Piudo, Ana, Gionchetti, Paolo, Roblin, Xavier, Seidler, Ursula, Andersson, David, Patel, Kamal, Desreumaux, Pierre, Saibeni, Simone, From, Gustav, Fedurco, Miroslav, Gregus, Milos, Bouhnik, Yoram, Luegering, Andreas, Cosintino, Rocco, Bunganic, Ivan, Ramos, Jaime, Aguas Peris, Mariam, Dewit, Olivier, Principi, Mariabeatrice, Wesley, Emma, Lago, Paula, Nancey, Stephane, Martín Arranz, María Dolores, Hindryckx, Pieter, Orlando, Ambrogio, Geccherle, Andrea, Annunziata, Maria Laura, Hayee, Bu'hussain, Balaz, Jozef, Portela, Francisco, Gilletta, Cyrielle, Kucharzik, Torsten, Mínguez, Miguel, Gisbert, Javier Pérez, Casbas, Ana Gutiérrez, Louis, Edouard, Marino, Marco, Parkes, Gareth, Cummings, Fraser, Jharap, Bindia, Kjeldsen, Jens, Correia, Luís, Ministro, Paula, Ebert, Matthias, Hertervig, Erik, Staessen, Dirk, Dutré, Joris, Colard, Arnaud, Morrison, Graham, Glerup, Henning, Dahlerup, Jens Frederik, Wolfhagen, Frank, Batovsky, Marian, Molnar, Martin, Kadleckova, Barbora, Caldeira, Paulo, Laharie, David, Hebuterne, Xavier, Bonaz, Bruno, Allez, Matthieu, Fischer, Andreas, Hinojosa Del Val, Joaquín Ernesto, Ciria, Miriam Mañosa, Herrera Justiniano, Jose Manuel, Soderman, Charlotte, Chandy, Rajiv, Mowat, Craig, Irving, Peter, Fallingborg, Jan, Matous, Jan, Douda, Tomas, Altwegg, Romain, Benitez, Jose Manuel, Arroyo Villarino, María Teresa, Capón, Jordi Guardiola, Vicenc, Daniel Ginard, Dewint, Pieter, Almer, Sven, Kindt, Sebastien, Danese, Silvio, Vermeire, Severine, D'Haens, Geert, Panés, Julian, Dignass, Axel, Magro, Fernando, Nazar, Maciej, Le Bars, Manuela, Lahaye, Marjolein, Ni, Lioudmila, Bravata, Ivana, Lavie, Frederic, Daperno, Marco, Lukáš, Milan, Armuzzi, Alessandro, Löwenberg, Mark, Gaya, Daniel R, and Peyrin-Biroulet, Laurent

Published
2022
Full Text
View/download PDF

5. Multicentre study and systematic review: Allopurinol exposure during pregnancy.

Author

Crouwel, Femke, Simsek, Melek, de Boer, Marjon A., van Asseldonk, Dirk P., Bhalla, Abha, Weusthuis, Angelique L. M., Gilissen, Lennard P. L., Verburg, Robert J., Mares, Wout G. N., Jharap, Bindia, Kuijvenhoven, Johan P., Oldenburg, Bas, Buiter, Hans J. C., Julsgaard, Mette, and de Boer, Nanne K.

Subjects
PREGNANCY, SMALL for gestational age, MULTIPLE pregnancy, ALLOPURINOL, PREGNANCY outcomes, INFLAMMATORY bowel diseases
Abstract

Summary: Background: Data about the safety of allopurinol in pregnant women are sparsely reported. Aims: To investigate the risk of adverse pregnancy outcome and congenital abnormalities after in utero exposure to allopurinol in inflammatory bowel disease (IBD) pregnancies and in general. Methods: We collected safety data of patients with IBD who were treated with allopurinol during pregnancy between January 2013 and March 2022. Additionally, we performed a systematic review about the teratogenic potential of allopurinol. Results: We collected data from 42 allopurinol‐exposed pregnancies, including one twin pregnancy; in all women, allopurinol was combined with a thiopurine. Six pregnancies (14.3%) resulted in miscarriage and one in stillbirth at 32 weeks. A congenital anomaly was observed in one newborn (coarctation of the aorta discovered postpartum). Three pregnancies, including the twin pregnancy, ended in moderate preterm delivery and one in very preterm delivery. Five neonates (15.2%) were small for gestational age. From our literature search, we identified an additional 102 allopurinol‐exposed pregnancies resulting in 129 live births, including 36 infants from our cohort. Ten infants (7.8%) were born with a congenital anomaly. Two (1.6%) had a comparable pattern of multiple anomalies. The systematic review sub‐analysis including only infants born to mothers with IBD (n = 76) revealed that 2.6% of infants had congenital anomalies after in utero exposure to a low dose of allopurinol. Conclusions: Overall, the teratogenicity of allopurinol remains inconclusive. Children conceived by mothers treated for IBD with allopurinol/thiopurine co‐therapy do not seem to have an increased risk of congenital anomalies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Multicentre study and systematic review: Allopurinol exposure during pregnancy

Author

MS MDL 1, Infection & Immunity, Crouwel, Femke, Simsek, Melek, de Boer, Marjon A, van Asseldonk, Dirk P, Bhalla, Abha, Weusthuis, Angelique L M, Gilissen, Lennard P L, Verburg, Robert J, Mares, Wout G N, Jharap, Bindia, Kuijvenhoven, Johan P, Oldenburg, Bas, Buiter, Hans J C, Julsgaard, Mette, de Boer, Nanne K, MS MDL 1, Infection & Immunity, Crouwel, Femke, Simsek, Melek, de Boer, Marjon A, van Asseldonk, Dirk P, Bhalla, Abha, Weusthuis, Angelique L M, Gilissen, Lennard P L, Verburg, Robert J, Mares, Wout G N, Jharap, Bindia, Kuijvenhoven, Johan P, Oldenburg, Bas, Buiter, Hans J C, Julsgaard, Mette, and de Boer, Nanne K

Published
2024

7. Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease: A Prospective Study Based on Clinical Risk Stratification

Author

MS MDL 1, Arkenbosch, Jeanine H.C., Beelen, Evelien M.J., Dijkstra, Gerard, Romberg-Camps, Mariëlle, Duijvestein, Marjolijn, Hoentjen, Frank, Van Der Marel, Sander, Maljaars, P. W.Jeroen, Jansen, Sita, De Boer, Nanne K.H., West, Rachel L., Horjus, Carmen S., Stassen, Laurents P.S., Van Schaik, Fiona D.M., Van Ruler, Oddeke, Jharap, Bindia J.H., Visschedijk, Marijn, Janssen, Alfred, Erler, Nicole S., Doukas, Michail, Ooms, Ariadne H.A.G., Kats-Ugurlu, Gursah, Van Der Woude, Christien Janneke, De Vries, Annemarie C., MS MDL 1, Arkenbosch, Jeanine H.C., Beelen, Evelien M.J., Dijkstra, Gerard, Romberg-Camps, Mariëlle, Duijvestein, Marjolijn, Hoentjen, Frank, Van Der Marel, Sander, Maljaars, P. W.Jeroen, Jansen, Sita, De Boer, Nanne K.H., West, Rachel L., Horjus, Carmen S., Stassen, Laurents P.S., Van Schaik, Fiona D.M., Van Ruler, Oddeke, Jharap, Bindia J.H., Visschedijk, Marijn, Janssen, Alfred, Erler, Nicole S., Doukas, Michail, Ooms, Ariadne H.A.G., Kats-Ugurlu, Gursah, Van Der Woude, Christien Janneke, and De Vries, Annemarie C.

Published
2023

8. Prophylactic medication for the prevention of endoscopic recurrence in Crohn's disease:a prospective study based on clinical risk stratification

Author

Arkenbosch, Jeanine H C, Beelen, Evelien M J, Dijkstra, Gerard, Romberg-Camps, Mariëlle, Duijvestein, Marjolijn, Hoentjen, Frank, van der Marel, Sander, Maljaars, P W Jeroen, Jansen, Sita, de Boer, Nanne K H, West, Rachel L, Horjus, Carmen S, Stassen, Laurents P S, van Schaik, Fiona D M, van Ruler, Oddeke, Jharap, Bindia J H, Visschedijk, Marijn, Janssen, Alfred, Erler, Nicole S, Doukas, Michail, Ooms, Ariadne H A G, Kats-Ugurlu, Gursah, van der Woude, C Janneke, de Vries, Annemarie C, Arkenbosch, Jeanine H C, Beelen, Evelien M J, Dijkstra, Gerard, Romberg-Camps, Mariëlle, Duijvestein, Marjolijn, Hoentjen, Frank, van der Marel, Sander, Maljaars, P W Jeroen, Jansen, Sita, de Boer, Nanne K H, West, Rachel L, Horjus, Carmen S, Stassen, Laurents P S, van Schaik, Fiona D M, van Ruler, Oddeke, Jharap, Bindia J H, Visschedijk, Marijn, Janssen, Alfred, Erler, Nicole S, Doukas, Michail, Ooms, Ariadne H A G, Kats-Ugurlu, Gursah, van der Woude, C Janneke, and de Vries, Annemarie C

Abstract

BACKGROUND: To prevent recurrence after ileocolonic resection [ICR] in Crohn's disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. METHODS: In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts' score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. RESULTS: In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61-0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64-0.81]. CONCLUSION: Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed.

Published
2023

9. Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study

Author

MS MDL 1, Cancer, Infection & Immunity, Simsek, Melek, Schepers, Femke, Kaplan, Sigal, Van Asseldonk, Dirk, Van Boeckel, Petra, Boekema, Paul, Dijkstra, Gerard, Fidder, Herma, Gisbertz, Ingrid, Hoentjen, Frank, Jharap, Bindia, Kubben, Frank, De Leest, Marleen, Meijssen, Maarten, Petrak, Ana, Van De Poel, Else, Russel, Maurice, Van Bodegraven, Adriaan A., Mulder, Chris J.J., De Boer, Nanne, MS MDL 1, Cancer, Infection & Immunity, Simsek, Melek, Schepers, Femke, Kaplan, Sigal, Van Asseldonk, Dirk, Van Boeckel, Petra, Boekema, Paul, Dijkstra, Gerard, Fidder, Herma, Gisbertz, Ingrid, Hoentjen, Frank, Jharap, Bindia, Kubben, Frank, De Leest, Marleen, Meijssen, Maarten, Petrak, Ana, Van De Poel, Else, Russel, Maurice, Van Bodegraven, Adriaan A., Mulder, Chris J.J., and De Boer, Nanne

Published
2023

10. Thioguanine is effective as maintenance therapy for inflammatory bowel disease: a prospective multicentre registry study

Author

Simsek, Melek, primary, Schepers, Femke, additional, Kaplan, Sigal, additional, van Asseldonk, Dirk, additional, van Boeckel, Petra, additional, Boekema, Paul, additional, Dijkstra, Gerard, additional, Fidder, Herma, additional, Gisbertz, Ingrid, additional, Hoentjen, Frank, additional, Jharap, Bindia, additional, Kubben, Frank, additional, de Leest, Marleen, additional, Meijssen, Maarten, additional, Petrak, Ana, additional, van de Poel, Else, additional, Russel, Maurice, additional, van Bodegraven, Adriaan A, additional, Mulder, Chris J J, additional, and de Boer, Nanne, additional

Published
2023
Full Text
View/download PDF

11. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

Author

Straatmijer, Tessa, primary, Biemans, Vince B.C., additional, Visschedijk, Marijn, additional, Hoentjen, Frank, additional, de Vries, Annemarie, additional, van Bodegraven, Adriaan A., additional, Bodelier, Alexander, additional, de Boer, Nanne K.H., additional, Dijkstra, Gerard, additional, Festen, Noortje, additional, Horjus, Carmen, additional, Jansen, Jeroen M., additional, Jharap, Bindia, additional, Mares, Wout, additional, van Schaik, Fiona D.M., additional, Ponsioen, Cyriel, additional, Romkens, Tessa, additional, Srivastava, Nidhi, additional, van der Voorn, Michael M.P. J.A., additional, West, Rachel, additional, van der Woude, Janneke, additional, Wolvers, Marije D.J., additional, Pierik, Marieke, additional, van der Meulen-de Jong, Andrea E., additional, Duijvestein, Marjolijn, additional, Schlotter, Malena, additional, van Workum, Martine, additional, de Jong, Dirk, additional, van Dop, Willemijn, additional, van der Marel, S., additional, El Ghabzouri, Hayat, additional, Talhaoui, Kamila, additional, Oldenburg, Bas, additional, Boontje, Nynke, additional, Fidder, Herma, additional, Hirdes, Meike, additional, Creemers, Rob H., additional, Hoekstra, J., additional, Smid, Jael, additional, Mujagic, Zlatan, additional, François-Verweij, Marthe, additional, Schakel- van den Berge, Toos, additional, Maljaars, Jeroen, additional, Theeuwen, Rosaline, additional, van den Berg, Denise, additional, Gerretsen, Suzanne, additional, Yocarini, Xenia, additional, D’Haens, Geert, additional, Lowenberg, Mark, additional, Grootjans, Joep, additional, Gecse, Krisztina, additional, Bouma, Gerd, additional, Waaijenberg, Petra, additional, and Muskens, Bart, additional

Published
2023
Full Text
View/download PDF

12. Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease

Author

Crouwel, Femke, primary, Simsek, Melek, additional, de Boer, Marjon A, additional, Mulder, Chris J J, additional, van Andel, Emma M, additional, Creemers, Rob H, additional, van Asseldonk, Dirk P, additional, van Bodegraven, Ad A, additional, Horjus, Carmen S, additional, Visschedijk, Marijn C, additional, Weusthuis, Angelique L M, additional, Seinen, Margien L, additional, Jharap, Bindia, additional, van Schaik, Fiona D M, additional, Ahmad, Ishfaq, additional, Boekema, Paul J, additional, Tack, Greetje J, additional, Wormmeester, Louktje, additional, Lutgens, Maurice W M D, additional, van Boeckel, Petra G A, additional, Gilissen, Lennard P L, additional, Kerkhof, Marjon, additional, Russel, Maurice G V M, additional, Hoentjen, Frank, additional, Bartelink, Maartje E, additional, Kuijvenhoven, Johan P, additional, Maljaars, Jeroen W J, additional, van Dop, Willemijn A, additional, Wonders, Janneke, additional, van der Voorn, Michael M P J A, additional, Buiter, Hans J C, additional, and de Boer, Nanne K, additional

Published
2022
Full Text
View/download PDF

13. Anemia and Iron Deficiency in Outpatients with Inflammatory Bowel Disease: Ubiquitous Yet Suboptimally Managed

Author

Loveikyte, Roberta, primary, Boer, Menno, additional, van der Meulen, Catharina N., additional, ter Steege, Rinze W. F., additional, Tack, Greetje, additional, Kuyvenhoven, Johan, additional, Jharap, Bindia, additional, Vu, My K., additional, Vogelaar, Lauran, additional, West, Rachel L., additional, van der Marel, Sander, additional, Römkens, Tessa E. H., additional, Mujagic, Zlatan, additional, Hoentjen, Frank, additional, van Bodegraven, Adriaan A., additional, van Schaik, Fiona D. M., additional, de Vries, Annemarie C., additional, Dijkstra, Gerard, additional, and van der Meulen-de Jong, Andrea E., additional

Published
2022
Full Text
View/download PDF

14. Reply

Author

Mahmoud, Remi, primary, Savelkoul, Edo H.J., additional, Jharap, Bindia, additional, and Oldenburg, Bas, additional

Published
2022
Full Text
View/download PDF

15. Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn’s Disease: a Prospective Study Based on Clinical Risk Stratification

Author

Arkenbosch, Jeanine H C, primary, Beelen, Evelien M J, additional, Dijkstra, Gerard, additional, Romberg-Camps, Mariëlle, additional, Duijvestein, Marjolijn, additional, Hoentjen, Frank, additional, van der Marel, Sander, additional, Maljaars, P W Jeroen, additional, Jansen, Sita, additional, de Boer, Nanne K H, additional, West, Rachel L, additional, Horjus, Carmen S, additional, Stassen, Laurents P S, additional, van Schaik, Fiona D M, additional, van Ruler, Oddeke, additional, Jharap, Bindia J H, additional, Visschedijk, Marijn, additional, Janssen, Alfred, additional, Erler, Nicole S, additional, Doukas, Michail, additional, Ooms, Ariadne H A G, additional, Kats-Ugurlu, Gursah, additional, van der Woude, C Janneke, additional, and de Vries, Annemarie C, additional

Published
2022
Full Text
View/download PDF

16. Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.

Author

Crouwel, Femke, Simsek, Melek, Boer, Marjon A de, Mulder, Chris J J, Andel, Emma M van, Creemers, Rob H, Asseldonk, Dirk P van, Bodegraven, Ad A van, Horjus, Carmen S, Visschedijk, Marijn C, Weusthuis, Angelique L M, Seinen, Margien L, Jharap, Bindia, Schaik, Fiona D M van, Ahmad, Ishfaq, Boekema, Paul J, Tack, Greetje J, Wormmeester, Louktje, Lutgens, Maurice W M D, and Boeckel, Petra G A van

Abstract

Background Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the safety of thioguanine during pregnancy and birth. Methods In this multicentre case series, IBD patients treated with thioguanine during pregnancy were included. Data regarding disease and medication history, pregnancy course, obstetric complications, and neonatal outcomes were collected. Results Data on 117 thioguanine-exposed pregnancies in 99 women were collected. Most [78%] had Crohn's disease and the mean age at delivery was 31 years. In 18 pregnancies [15%], IBD flared. Obstetric and infectious complications were seen in 15% [ n  = 17] and 7% [ n  = 8] of pregnancies, respectively. Ten pregnancies [8.5%] resulted in a first trimester miscarriage, one in a stillbirth at 22 weeks of gestational age and one in an induced abortion due to trisomy 21. In total, 109 neonates were born from 101 singleton pregnancies and four twin pregnancies. One child was born with a congenital abnormality [cleft palate]. In the singleton pregnancies, 10 children were born prematurely and 10 were born small for gestational age. Screening for myelosuppresion was performed in 16 neonates [14.7%]; two had anaemia in umbilical cord blood. All outcomes were comparable to either the general Dutch population or to data from three Dutch cohort studies on the use of conventional thiopurines in pregnant IBD patients. Conclusion In this large case series, the use of thioguanine during pregnancy is not associated in excess with adverse maternal or neonatal outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. 721: IMMUNOMODULATOR WITHDRAWAL FROM ANTI-TNF THERAPY IS NOT ASSOCIATED WITH LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE

Author

Mahmoud, Remi, primary, Schultheiss, Johannes P., additional, Louwers, Jonas M., additional, Kaaij, Michiel T. van der, additional, Hellemondt, Boris P. van, additional, Mahmmod, Nofel, additional, Boeckel, Petra G. van, additional, Jharap, Bindia, additional, Fidder, Herma H., additional, and Oldenburg, Bas, additional

Published
2022
Full Text
View/download PDF

18. Tu1498: WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY

Author

Savelkoul, Edo, primary, Mahmoud, Remi, additional, Jong, Dirk J. De, additional, Dop, Willemijn A. van, additional, Romkens, Tessa E.H, additional, Nissen, Loes H., additional, Mahmmod, Nofel, additional, Boeckel, Petra G. van, additional, Lutgens, Maurice, additional, Mares, Wout, additional, Epping, Ludger, additional, Minderhoud, Itta M., additional, Jansen, Jeroen M., additional, Gisbertz, Ingrid A., additional, Boekema, Paul, additional, Koning, Daan de, additional, Horje, Carmen S. Horjus Talabur, additional, Jharap, Bindia, additional, Oldenburg, Bas, additional, and Hoentjen, Frank, additional

Published
2022
Full Text
View/download PDF

19. Mo1539: ANTI-TNF WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN ENDOSCOPIC REMISSION: A PROSPECTIVE STUDY

Author

Mahmoud, Remi, primary, Savelkoul, Edo, additional, Mares, Wout, additional, Goetgebuer, Rogier, additional, Witteman, Ben, additional, Koning, Daan de, additional, Minderhoud, Itta M., additional, Tuyl, Sebastiaan van, additional, Boeckel, Petra G. van, additional, Mahmmod, Nofel, additional, Lutgens, Maurice, additional, Horje, Carmen S. Horjus Talabur, additional, Romkens, Tessa E.H, additional, Akol-Simsek, Dilek, additional, Jansen, Jeroen M., additional, Colombel, Jean Frederic, additional, Hoentjen, Frank, additional, Jharap, Bindia, additional, and Oldenburg, Bas, additional

Published
2022
Full Text
View/download PDF

20. Mo1804 IMAGING-BASED PREOPERATIVE BODY COMPOSITION IS ASSOCIATED WITH THE RISK OF POSTOPERATIVE COMPLICATIONS AND POSTOPERATIVE ENDOSCOPIC RECURRENCE IN PATIENTS WITH CROHN'S DISEASE

Author

Bak, Michiel T., Demers, Karlijn, van Ruler, Oddeke, Pierik, Marie J., van der Bilt, Jarmila D.W., Romberg-Camps, Mariëlle, Dijkstra, Gerard, Duijvestein, Marjolijn, van der Marel, Sander, Maljaars, Jeroen, Buskens, Christianne J., Bakers, Frans C., van Dijk, David P., Brecheisen, Ralph, Bongers, Bart C., van Rossum, Elisabeth F., de Witte, Dennis, Jansen, Sita, Jharap, Bindia, Horje, Carmen S. Horjus Talabur, Van Schaik, Fiona, West, Rachel, De Boer, Nanne, Van Der Woude, Christien Janneke, Stassen, Laurents P., and De Vries, Annemarie C.

Published
2024
Full Text
View/download PDF

21. Su1839 IDENTIFICATION OF CLINICAL RISK FACTORS FOR POSTOPERATIVE ENDOSCOPIC RECURRENCE IN CROHN'S DISEASE: A PROSPECTIVE, MULTICENTER COHORT STUDY

Author

Bak, Michiel T., Beelen, Evelien, van der Bilt, Jarmila D.W., Romberg-Camps, Mariëlle, Dijkstra, Gerard, Duijvestein, Marjolijn, van der marel, Sander, Stassen, Laurents P., Maljaars, Jeroen, Buskens, Christianne J., Jansen, Sita, Jharap, Bindia, Horje, Carmen S. Horjus Talabur, Van Schaik, Fiona, West, Rachel, de Boer, Nanne, Van Der Woude, Christien Janneke, van Ruler, Oddeke, and De Vries, Annemarie C.

Published
2024
Full Text
View/download PDF

23. Anemia and Iron Deficiency in Outpatients with Inflammatory Bowel Disease:Ubiquitous Yet Suboptimally Managed

Author

Loveikyte, Roberta, Boer, Menno, van der Meulen, Catharina N., ter Steege, Rinze W.F., Tack, Greetje, Kuyvenhoven, Johan, Jharap, Bindia, Vu, My K., Vogelaar, Lauran, West, Rachel L., van der Marel, Sander, Römkens, Tessa E.H., Mujagic, Zlatan, Hoentjen, Frank, van Bodegraven, Adriaan A., van Schaik, Fiona D.M., de Vries, Annemarie C., van der Meulen-de Jong, Andrea E., Loveikyte, Roberta, Boer, Menno, van der Meulen, Catharina N., ter Steege, Rinze W.F., Tack, Greetje, Kuyvenhoven, Johan, Jharap, Bindia, Vu, My K., Vogelaar, Lauran, West, Rachel L., van der Marel, Sander, Römkens, Tessa E.H., Mujagic, Zlatan, Hoentjen, Frank, van Bodegraven, Adriaan A., van Schaik, Fiona D.M., de Vries, Annemarie C., and van der Meulen-de Jong, Andrea E.

Abstract

Background: Iron deficiency (ID) and anemia in patients with Inflammatory Bowel Disease (IBD) are associated with a reduced quality of life. We assessed the prevalence of ID and anemia in Dutch outpatients with IBD and compared routine ID(A) management among medical professionals to the European Crohn’s and Colitis Organisation (ECCO) treatment guidelines. Methods: Between January and November 2021, consecutive adult outpatients with IBD were included in this study across 16 Dutch hospitals. Clinical and biochemical data were extracted from medical records. Additionally, medical professionals filled out questionnaires regarding routine ID(A) management. Results: In total, 2197 patients (1271 Crohn’s Disease, 849 Ulcerative Colitis, and 77 IBD-unclassified) were included. Iron parameters were available in 59.3% of cases. The overall prevalence of anemia, ID, and IDA was: 18.0%, 43.4%, and 12.2%, respectively. The prevalence of all three conditions did not differ between IBD subtypes. ID(A) was observed more frequently in patients with biochemically active IBD than in quiescent IBD (ID: 70.8% versus 23.9%; p < 0.001). Contrary to the guidelines, most respondents prescribed standard doses of intravenous or oral iron regardless of biochemical parameters or inflammation. Lastly, 25% of respondents reported not treating non-anemic ID. Conclusions: One in five patients with IBD suffers from anemia that—despite inconsistently measured iron parameters—is primarily caused by ID. Most medical professionals treat IDA with oral iron or standard doses of intravenous iron regardless of biochemical inflammation; however, non-anemic ID is often overlooked. Raising awareness about the management of ID(A) is needed to optimize and personalize routine care.

Published
2022

24. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Author

Danese, Silvio, primary, Vermeire, Severine, additional, D'Haens, Geert, additional, Panés, Julian, additional, Dignass, Axel, additional, Magro, Fernando, additional, Nazar, Maciej, additional, Le Bars, Manuela, additional, Lahaye, Marjolein, additional, Ni, Lioudmila, additional, Bravata, Ivana, additional, Lavie, Frederic, additional, Daperno, Marco, additional, Lukáš, Milan, additional, Armuzzi, Alessandro, additional, Löwenberg, Mark, additional, Gaya, Daniel R, additional, Peyrin-Biroulet, Laurent, additional, Rocca, Rodolfo, additional, Lopes, Susana, additional, Caprioli, Flavio, additional, Ardizzone, Sandro, additional, Echarri Piudo, Ana, additional, Gionchetti, Paolo, additional, Roblin, Xavier, additional, Seidler, Ursula, additional, Andersson, David, additional, Patel, Kamal, additional, Desreumaux, Pierre, additional, Saibeni, Simone, additional, From, Gustav, additional, Fedurco, Miroslav, additional, Gregus, Milos, additional, Bouhnik, Yoram, additional, Luegering, Andreas, additional, Cosintino, Rocco, additional, Bunganic, Ivan, additional, Ramos, Jaime, additional, Aguas Peris, Mariam, additional, Dewit, Olivier, additional, Principi, Mariabeatrice, additional, Wesley, Emma, additional, Lago, Paula, additional, Nancey, Stephane, additional, Martín Arranz, María Dolores, additional, Hindryckx, Pieter, additional, Orlando, Ambrogio, additional, Geccherle, Andrea, additional, Annunziata, Maria Laura, additional, Hayee, Bu'hussain, additional, Balaz, Jozef, additional, Portela, Francisco, additional, Gilletta, Cyrielle, additional, Kucharzik, Torsten, additional, Mínguez, Miguel, additional, Gisbert, Javier Pérez, additional, Casbas, Ana Gutiérrez, additional, Louis, Edouard, additional, Marino, Marco, additional, Parkes, Gareth, additional, Cummings, Fraser, additional, Jharap, Bindia, additional, Kjeldsen, Jens, additional, Correia, Luís, additional, Ministro, Paula, additional, Ebert, Matthias, additional, Hertervig, Erik, additional, Staessen, Dirk, additional, Dutré, Joris, additional, Colard, Arnaud, additional, Morrison, Graham, additional, Glerup, Henning, additional, Dahlerup, Jens Frederik, additional, Wolfhagen, Frank, additional, Batovsky, Marian, additional, Molnar, Martin, additional, Kadleckova, Barbora, additional, Caldeira, Paulo, additional, Laharie, David, additional, Hebuterne, Xavier, additional, Bonaz, Bruno, additional, Allez, Matthieu, additional, Fischer, Andreas, additional, Hinojosa Del Val, Joaquín Ernesto, additional, Ciria, Miriam Mañosa, additional, Herrera Justiniano, Jose Manuel, additional, Soderman, Charlotte, additional, Chandy, Rajiv, additional, Mowat, Craig, additional, Irving, Peter, additional, Fallingborg, Jan, additional, Matous, Jan, additional, Douda, Tomas, additional, Altwegg, Romain, additional, Benitez, Jose Manuel, additional, Arroyo Villarino, María Teresa, additional, Capón, Jordi Guardiola, additional, Vicenc, Daniel Ginard, additional, Dewint, Pieter, additional, Almer, Sven, additional, and Kindt, Sebastien, additional

Published
2022
Full Text
View/download PDF

25. Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease: a Prospective Study Based on Clinical Risk Stratification.

Author

Arkenbosch, Jeanine H C, Beelen, Evelien M J, Dijkstra, Gerard, Romberg-Camps, Mariëlle, Duijvestein, Marjolijn, Hoentjen, Frank, van der Marel, Sander, Maljaars, P W Jeroen, Jansen, Sita, Boer, Nanne K H de, West, Rachel L, Horjus, Carmen S, Stassen, Laurents P S, Schaik, Fiona D M van, Ruler, Oddeke van, Jharap, Bindia J H, Visschedijk, Marijn, Janssen, Alfred, Erler, Nicole S, and Doukas, Michail

Abstract

Background To prevent recurrence after ileocolonic resection [ICR] in Crohn's disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. Methods In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts' score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. Results In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61–0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64–0.81]. Conclusion Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Reply

Author

Mahmoud, Remi, Savelkoul, Edo H.J., Jharap, Bindia, and Oldenburg, Bas

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results